Glimepiride

證據等級: L5

預測適應症: 9 個

Glimepiride: From Type 2 Diabetes Mellitus to Focal Stiff Limb Syndrome

One-Sentence Summary

Glimepiride is a sulfonylurea antidiabetic drug used to manage Type 2 Diabetes Mellitus by stimulating pancreatic insulin secretion. The TxGNN model predicts it may be effective for Focal Stiff Limb Syndrome, but this prediction is currently supported by 0 clinical trials and 0 publications — it is a pure graph-embedding signal with no pharmacological or clinical evidence behind it.

Quick Overview

Item	Content
Original Indication	Type 2 Diabetes Mellitus (inferred from sulfonylurea drug class; not present in the evidence pack's license records)
Predicted New Indication	Focal Stiff Limb Syndrome
TxGNN Prediction Score	99.75%
Evidence Level	L5
Finland Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available for this candidate (flagged as a blocking-severity data gap). Based on known pharmacology, glimepiride is a sulfonylurea that binds SUR1 on the pancreatic β-cell KATP channel to trigger insulin release, and its efficacy in Type 2 Diabetes Mellitus is well established.

Focal stiff limb syndrome is a localized variant of stiff person syndrome, a rare autoimmune neurological disorder in which anti-GAD65 antibodies attack GABAergic neurons, causing muscle rigidity and spasm. There is no established pharmacological or clinical relationship between insulin-secretagogue activity and this autoimmune neuromuscular condition.

The evidence pack's own rationale for this prediction is explicit that the link is not mechanistically grounded: it states that no sulfonylurea pharmacological mechanism supports the connection, and that the high TxGNN score likely reflects an indirect statistical association in the knowledge graph (possibly via GAD/insulin-pathway gene overlap with adjacent predictions) rather than biological plausibility. No clinical or molecular evidence currently exists to support this indication.

Clinical Trial Evidence

Currently no related clinical trials registered

Literature Evidence

Currently no related literature available

Safety Considerations

Please refer to the package insert for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale: This is an L5 prediction (model output only) with no clinical trials, no supporting literature, and no plausible pharmacological mechanism connecting glimepiride's insulin-secretagogue action to the autoimmune pathophysiology of focal stiff limb syndrome — the evidence pack's own rationale flags the mechanistic link as absent.

To proceed, the following is needed:

TFDA/Fimea package insert data (warnings, contraindications) — currently a blocking data gap
Verified mechanism of action (MOA) data from DrugBank — currently a high-severity data gap
Preclinical or mechanistic studies establishing biological plausibility for this indication
Drug interaction (DDI) data, currently unavailable
If pursued, note that other predicted indications for glimepiride (e.g., pancreatic agenesis, rank 9) carry a marginally stronger — though still weak — mechanistic rationale via monogenic neonatal diabetes and may warrant comparative prioritization
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.